Original Article

Simultaneous detection and differentiation of Mycobacterium tuberculosis and nontuberculous mycobacteria coexisting in patients with pulmonary tuberculosis by single-tube multiplex PCR

Abstract

Background and Objectives: In clinical diagnostics, molecular methods are used to detect Mycobacterium tuberculosis bacilli (MTB) and to distinguish them from non-tuberculous mycobacteria (NTM). They are also used to make the right treatment decision for the patient as soon as possible. The aim of this study was to establish a rapid and novel multiplex PCR (mPCR) assay for the detection and differentiation of MTB and NTM in a single tube.
Materials and Methods: 100 sputum samples positive for acid-fast bacilli (AFB) were included in this study. Mycobacterial culture, biochemical tests, and antibiotic susceptibility testing were performed on samples. After alkaline decontamination, total DNA was extracted from the samples. A primer pair targeting the rpoB gene, encoding the beta-subunit of RNA polymerase, was used to detect MTB and NTM, amplifying a 235-bp fragment of MTB and a 136-bp sequence of NTM. A pair of primers targeting a 190-bp fragment of the IS6110 region of MTB was also used to confirm the results. The sensitivity and specificity of the mPCR assay were evaluated using DNA extracted from standard strains. The amplified products were then analyzed by conventional agarose gel electrophoresis.
Results: Of 100 AFB smear-positive sputum samples, 92 MTB DNA, 7 NTM DNA, and one mixed-infection sample were identified in a single tube using mPCR assay. There was no correlation between the AFB degree of smear positivity and PCR results. Of seven NTM isolates, 6 (86%) were resistant to rifampin, isoniazid, and ethambutol, the three first-line anti-tuberculosis drugs.
Conclusion: A single-tube mPCR assay based on the rpoB gene provides a rapid and reliable means of detecting and differentiating MTB and NTM in sputum specimens.

1. Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int J Infect Dis 2022; 124 Suppl 1: S12-S19.
2. McQuaid CF, McCreesh N, Read JM, Sumner T, Houben RM, White RG, et al. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J 2020; 56: 2001718.
3. Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. MedRxiv 2020.
4. Togun T, Kampmann B, Stoker NG, Lipman M. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. Ann Clin Microbiol Antimicrob 2020; 19: 21.
5. Koh W-J. Nontuberculous mycobacteria—overview. Microbiol Spectr 2017; 5: 10.1128/microbiolspec.TNMI7-0024-2016.
6. MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global epidemiology of tuberculosis and progress toward achieving global targets—2017. MMWR Morb Mortal Wkly Rep 2019; 68: 263-266.
7. Niederman MS, Zumla A. Editorial: Toward improving the diagnosis, treatment and prevention of community acquired and nosocomial respiratory tract infections. Curr Opin Pulm Med 2019; 25: 217-219.
8. Saxena S, Spaink HP, Forn-Cuní G. Drug resistance in nontuberculous mycobacteria: mechanisms and models. Biology (Basel) 2021; 10: 96.
9. Pennington KM, Vu A, Challener D, Rivera CG, Shweta F, Zeuli JD, et al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis 2021; 24: 100244.
10. Huang M, Tan Y, Zhang X, Wang Y, Su B, Xue Z, et al. Effect of mixed infections with Mycobacterium tuberculosis and nontuberculous Mycobacteria on diagnosis of multidrug-resistant tuberculosis: A retrospective multicentre study in China. Infect Drug Resist 2022; 15: 157-166.
11. Thangavelu K, Krishnakumariamma K, Pallam G, Prakash DD, Chandrashekar L, Kalaiarasan E, et al. Prevalence and speciation of non-tuberculous mycobacteria among pulmonary and extrapulmonary tuberculosis suspects in South India. J Infect Public Health 2021; 14: 320-323.
12. Acharya B, Acharya A, Gautam S, Ghimire SP, Mishra G, Parajuli N, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Mol Biol Rep 2020; 47: 4065-4075.
13. Elhassan MM, Elmekki MA, Osman AL, Hamid ME. Challenges in diagnosing tuberculosis in children: a comparative study from Sudan. Int J Infect Dis 2016; 43: 25-29.
14. Cowan JF, Chandler AS, Kracen E, Park DR, Wallis CK, Liu E, et al. Clinical impact and cost-effectiveness of Xpert MTB/RIF testing in hospitalized patients with presumptive pulmonary tuberculosis in the United States. Clin Infect Dis 2017; 64: 482-489.
15. Evans CA. GeneXpert—a game-changer for tuberculosis control? PLoS Med 2011; 8(7): e1001064.
16. Sciences CfIOoM. International ethical guidelines for biomedical research involving human subjects. Bull Med Ethics 2002; (182): 17-23.
17. World Health Organization. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. 2018.
18. Vago L, Barberis M, Gori A, Scarpellini P, Sala E, Nebuloni M, et al. Nested polymerase chain reaction for Mycobacterium tuberculosis IS6110 sequence on formalin-fixed paraffin-embedded tissues with granulomatous diseases for rapid diagnosis of tuberculosis. Am J Clin Pathol 1998; 109: 411-415.
19. Zhou L, Ma C, Xiao T, Li M, Liu H, Zhao X, et al. A new single gene differential biomarker for Mycobacterium tuberculosis complex and non-tuberculosis mycobacteria. Front Microbiol 2019; 10: 1887.
20. Izadi N, Mohammad Derakhshan, Samiei A, Ghazvini K. Co-infection of long-standing extensively drug-resistant Mycobacterium tuberculosis (XDR-TB) and non-tuberculosis mycobacteria: a case report. Respir Med Case Rep 2014; 15: 12-13.
21. Marino A, Cosentino F, Moscatt V, Pampaloni A. Coinfection by Mycobacterium tuberculosis and Mycobacterium chelonae in a patient with hairy cell leukemia: clinical and therapeutic management. Eur J Mol Clin Med 2021; 8: 3558-3563.
22. Ustinova VV, Smirnova TG, Sochivko DG, Varlamov DA, Larionova EE, Andreevskaya SN, et al. New assay to diagnose and differentiate between Mycobacterium tuberculosis complex and nontuberculous mycobacteria. Tuberculosis (Edinb) 2019; 114: 17-23.
23. Hsing S-C, Weng S-F, Cheng K-C, Shieh J-M, Chen C-H, Chiang S-R, et al. Increased risk of pulmonary tuberculosis in patients with previous non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis 2013; 17: 928-933.
24. Sadio Sarro YD , Butzler MA, Sanogo F, Kodio O, Tolofoudie M, Goumane MS, et al. Development and clinical evaluation of a new multiplex PCR assay for a simultaneous diagnosis of tuberculous and nontuberculous mycobacteria. EBioMedicine 2021; 70: 103527.
25. Bar-On O, Mussaffi H, Mei-Zahav M, Prais D, Steuer G, Stafler P, et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros 2015; 14: 53-62.
26. Jaktaji RP, Zargampoor F. Expression of tolC and organic solvent tolerance of Escherichia coli ciprofloxacin resistant mutants. Iran J Pharm Res 2017; 16: 1185-1189.
27. Naidoo K, Dookie N. Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? Lancet Infect Dis 2022; 22(4): e121-e127.
Files
IssueVol 15 No 3 (2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v15i3.12900
Keywords
Isoniazid; Multiplex polymerase chain reaction; Mycobacterium tuberculosis; Nontuberculous mycobacteria; Rifampin; Sputum
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Heidari L, Rafiei Dehbidi G, Farhadi A, Sami Kashkooli G, Zarghampoor F, Namdari S, Seyyedi N, Amirzadh Fard S, Behzad-Behbahani A. Simultaneous detection and differentiation of Mycobacterium tuberculosis and nontuberculous mycobacteria coexisting in patients with pulmonary tuberculosis by single-tube multiplex PCR. Iran J Microbiol. 2023;15(3):401-407.